COMPETITIVE · MARKET STRUCTURE · SWITZERLAND
Sigma Advanced divests 36.52% stake in Swiss pharma firm
Change
Sigma Advanced Systems completed the divestment of its entire 36.52% equity stake in Extrovis AG, generating $15 million.
Why it matters
Sigma Advanced Systems sold its entire 36.52% equity stake in Extrovis AG, a Switzerland-based pharmaceutical company. The transaction generated $15 million in proceeds. The divestment forms part of Sigma's portfolio rationalisation and its transformation into a pure‑play aerospace and defence platform. Sigma has recently acquired Nasmyth and AS Strategic; the proceeds provide additional financial flexibility for aerospace and defence operations.
Implications
- • Adds $15 million of deployable capital earmarked for aerospace and defence activities.
- • Removes pharmaceutical-equity exposure to Extrovis AG from Sigma's balance sheet.
- • Concentrates capital allocation and strategic planning resources on aerospace and defence expansion.
Who is affected
- • Sigma Advanced Systems corporate management and capital allocators
- • Aerospace and defence business units, suppliers, and partners
- • Investors and shareholders in Sigma Advanced Systems
Source
Topics
Business & Markets Mergers & Acquisitions Aerospace & Defense